The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas.
At a press conference today (December 16), Science editor-in-chief Donald Kennedy and deputy editor for life sciences Katrina Kelner presented their side of the story in the ongoing controversy over a cloning paper the journal published this year. Since the article, last author Gerald Schatten of the University of Pittsburgh has pulled out of a collaboration with his Korean co-authors, and first author Woo-suk Hwang admitted to both illegally obtaining eggs and tampering with images. Both Sch
December 16, 2005|